Boston Scientific · Cardiovascular Treatment · Healthcare M&A · Penumbra Acquisition
Boston Scientific has agreed to acquire Penumbra for over $14 billion, enhancing its cardiovascular treatment portfolio, with shareholders having the option of cash or stock.